TH2-driven manifestations of inborn errors of immunity
- PMID: 38761995
- PMCID: PMC12295673
- DOI: 10.1016/j.jaci.2024.05.007
TH2-driven manifestations of inborn errors of immunity
Abstract
Monogenic lesions in pathways critical for effector functions responsible for immune surveillance, protection against autoinflammation, and appropriate responses to allergens and microorganisms underlie the pathophysiology of inborn errors of immunity (IEI). Variants in cytokine production, cytokine signaling, epithelial barrier function, antigen presentation, receptor signaling, and cellular processes and metabolism can drive autoimmunity, immunodeficiency, and/or allergic inflammation. Identification of these variants has improved our understanding of the role that many of these proteins play in skewing toward TH2-related allergic inflammation. Early-onset or atypical atopic disease, often in conjunction with immunodeficiency and/or autoimmunity, should raise suspicion for an IEI. This becomes a diagnostic dilemma if the initial clinical presentation is solely allergic inflammation, especially when the prevalence of allergic diseases is becoming more common. Genetic sequencing is necessary for IEI diagnosis and is helpful for early recognition and implementation of targeted treatment, if available. Although genetic evaluation is not feasible for all patients with atopy, identifying atopic patients with molecular immune abnormalities may be helpful for diagnostic, therapeutic, and prognostic purposes. In this review, we focus on IEI associated with TH2-driven allergic manifestations and classify them on the basis of the affected molecular pathways and predominant clinical manifestations.
Keywords: Inborn errors of immunity; allergic inflammation; asthma; atopic dermatitis; atopy; dysregulation; eosinophilia; immunomodulation; mast cell dysregulation; primary atopic disorders; primary immunodeficiency.
Published by Elsevier Inc.
Conflict of interest statement
Disclosure statement This work was supported in part by the Intramural Research Program of the National Institute of Allergy and Infectious Diseases at the National Institutes of Health. Disclosure of potential conflict of interest: J. D. Milner served on the scientific advisory board for Blueprint Medicine. The rest of the authors declare that they have no relevant conflicts of interest.
Figures

Similar articles
-
[Guidelines for the prevention and management of bronchial asthma (2024 edition)].Zhonghua Jie He He Hu Xi Za Zhi. 2025 Mar 12;48(3):208-248. doi: 10.3760/cma.j.cn112147-20241013-00601. Zhonghua Jie He He Hu Xi Za Zhi. 2025. PMID: 40050074 Chinese.
-
AGA Clinical Practice Update on GI Manifestations and Autonomic or Immune Dysfunction in Hypermobile Ehlers-Danlos Syndrome: Expert Review.Clin Gastroenterol Hepatol. 2025 Jul;23(8):1291-1302. doi: 10.1016/j.cgh.2025.02.015. Epub 2025 May 19. Clin Gastroenterol Hepatol. 2025. PMID: 40387691 Review.
-
Selected inborn errors of immunity associated with severe atopic phenotypes: Implications for the practicing allergist.Ann Allergy Asthma Immunol. 2025 Aug;135(2):162-168. doi: 10.1016/j.anai.2025.05.024. Epub 2025 May 29. Ann Allergy Asthma Immunol. 2025. PMID: 40449791 Review.
-
PTS-Related Tetrahydrobiopterin Deficiency (PTPSD).2025 Jul 10. In: Adam MP, Feldman J, Mirzaa GM, Pagon RA, Wallace SE, Amemiya A, editors. GeneReviews® [Internet]. Seattle (WA): University of Washington, Seattle; 1993–2025. 2025 Jul 10. In: Adam MP, Feldman J, Mirzaa GM, Pagon RA, Wallace SE, Amemiya A, editors. GeneReviews® [Internet]. Seattle (WA): University of Washington, Seattle; 1993–2025. PMID: 40638773 Free Books & Documents. Review.
-
Ornithine Transcarbamylase Deficiency.2013 Aug 29 [updated 2022 May 26]. In: Adam MP, Feldman J, Mirzaa GM, Pagon RA, Wallace SE, Amemiya A, editors. GeneReviews® [Internet]. Seattle (WA): University of Washington, Seattle; 1993–2025. 2013 Aug 29 [updated 2022 May 26]. In: Adam MP, Feldman J, Mirzaa GM, Pagon RA, Wallace SE, Amemiya A, editors. GeneReviews® [Internet]. Seattle (WA): University of Washington, Seattle; 1993–2025. PMID: 24006547 Free Books & Documents. Review.
Cited by
-
Inborn Errors of Immunity Presenting with Early-Onset Severe Atopy.Medicina (Kaunas). 2025 Jan 2;61(1):62. doi: 10.3390/medicina61010062. Medicina (Kaunas). 2025. PMID: 39859044 Free PMC article. Review.
-
Tissue-Resident Th2 Cells in Type 2 Immunity and Allergic Diseases.Immunol Rev. 2025 Mar;330(1):e70006. doi: 10.1111/imr.70006. Immunol Rev. 2025. PMID: 39981858 Review.
-
Rapid identification of primary atopic disorders (PAD) by a clinical landmark-guided, upfront use of genomic sequencing.Allergol Select. 2024 Oct 2;8:304-323. doi: 10.5414/ALX02520E. eCollection 2024. Allergol Select. 2024. PMID: 39381601 Free PMC article.
-
The genetics of hyper IgE syndromes.Front Immunol. 2025 Feb 18;16:1516068. doi: 10.3389/fimmu.2025.1516068. eCollection 2025. Front Immunol. 2025. PMID: 40040707 Free PMC article. Review.
-
Expanding the spectrum of IPEX: from new clinical findings to novel treatments.Curr Opin Allergy Clin Immunol. 2024 Dec 1;24(6):457-463. doi: 10.1097/ACI.0000000000001033. Epub 2024 Oct 11. Curr Opin Allergy Clin Immunol. 2024. PMID: 39475830 Free PMC article. Review.
References
-
- Harris NL, Loke P. Recent advances in type-2-cell-mediated immunity: insights from helminth infection. Immunity 2018;48:396. - PubMed
-
- Galli SJ, Gaudenzio N, Tsai M. Mast cells in inflammation and disease: recent progress and ongoing concerns. Annu Rev Immunol 2020;38:49–77. - PubMed
-
- Lyons JJ, Yi T. Mast cell tryptases in allergic inflammation and immediate hyper-sensitivity. Curr Opin Immunol 2021;72:94–106. - PubMed
Publication types
MeSH terms
Substances
Grants and funding
LinkOut - more resources
Full Text Sources